Source study unconfirmed
Story checked
I injected a weight loss peptide — my liver started failing days later (opens in a new tab)
nypost.com · 2026-10-30
Short answer
Source study unconfirmedStudy not confirmed.
The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
I injected a weight loss peptide — my liver started failing days later
nypost.com · 2026-10-30
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
No single source study could be confirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
View article claimsSearch result
Source study unconfirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
Source layer
The 3 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Also referencedpresented as the new finding
https://www.abc.net.au/news/2026-06-20/liver-failure-fake-retatrutide-health-risk/106814372
- Also referencedpresented as the new finding
https://nypost.com/2026/10/28/health/retatrutide-delivers-double-the-weight-loss-as-ozempic-study/
- Also referencedpresented as earlier work
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedMegan Hancocks decided to try a black-market peptide to lose weight after seeing glowing results online.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 5Not checkedAfter taking a product labeled as retatrutide, she developed acute liver failure within days.View evidenceHide evidence
As statedwithin days
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 5Not checkedThe article says the real retatrutide is still undergoing clinical trials and that anything sold online is a knockoff of uncertain purity, safety and efficacy.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 5Not checkedThe article reports that in the latest retatrutide trial, participants lost an average of 44.3 pounds (19.5%) on the lower dose and 47.4 pounds (20.9%) on the higher dose.View evidenceHide evidence
As stated44.3 pounds / 19.5% and 47.4 pounds / 20.9%
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 5Not checkedThe article says the Food and Drug Administration has warned about retatrutide and other unapproved compounded GLP-1 medications.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref, Europe PMC · 15 candidate papers
Single or multiple nutritional hormone receptor modulators for chronic kidney disease.
Clinical Kidney Journal · 2026 · PubMed
Pathology of acute liver failure
Acute Liver Failure · 1996 · Crossref
Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia.
2026 · Europe PMC
From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.
Frontiers in Pharmacology · 2026 · PubMed, Europe PMC
Medical management of acute liver failure
Acute Liver Failure · 1996 · Crossref